Patent: 6,162,432
✉ Email this page to a colleague
Summary for Patent: 6,162,432
| Title: | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| Abstract: | Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria. |
| Inventor(s): | Wallner; Barbara P. (Weston, MA), Cooper; Kevin D. (Ann Arbor, MI) |
| Assignee: | Biogen, Inc. (Cambridge, MA) The Regents of The University of Michigan (Ann Arbor, MI) |
| Application Number: | 08/466,465 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,162,432
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | 01/30/2003 | ⤷ Try a Trial | 2017-12-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,162,432
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9306866 | ⤷ Try a Trial |
| United States of America | 7323171 | ⤷ Try a Trial |
| United States of America | 6764681 | ⤷ Try a Trial |
| United States of America | 2006084107 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
